KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Xenon Pharmaceuticals (XENE) Other Non Operating Income: 2013-2025

Historic Other Non Operating Income for Xenon Pharmaceuticals (XENE) over the last 12 years, with Sep 2025 value amounting to -$89,000.

  • Xenon Pharmaceuticals' Other Non Operating Income fell 137.55% to -$89,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $166,000, marking a year-over-year decrease of 48.77%. This contributed to the annual value of -$1.1 million for FY2024, which is 634.67% down from last year.
  • As of Q3 2025, Xenon Pharmaceuticals' Other Non Operating Income stood at -$89,000, which was down 105.24% from $1.7 million recorded in Q2 2025.
  • In the past 5 years, Xenon Pharmaceuticals' Other Non Operating Income ranged from a high of $1.9 million in Q4 2021 and a low of -$2.4 million during Q3 2022.
  • Its 3-year average for Other Non Operating Income is $70,818, with a median of $35,000 in 2025.
  • In the last 5 years, Xenon Pharmaceuticals' Other Non Operating Income crashed by 1,760.16% in 2022 and then soared by 16,880.00% in 2025.
  • Xenon Pharmaceuticals' Other Non Operating Income (Quarterly) stood at $1.9 million in 2021, then tumbled by 68.13% to $602,000 in 2022, then slumped by 114.95% to -$90,000 in 2023, then slumped by 1,542.22% to -$1.5 million in 2024, then slumped by 137.55% to -$89,000 in 2025.
  • Its Other Non Operating Income was -$89,000 in Q3 2025, compared to $1.7 million in Q2 2025 and $35,000 in Q1 2025.